Babatunde A. Ayodele

Babatunde A. Ayodele

Auto-generated profile, based on publicly available information

Babatunde A. Ayodele

Veterinary Bioscience, Melbourne Veterinary School, Faculty of Science, The University of Melbourne, Parkville, Victoria 3010, Australia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2018 in Equine Veterinary Journal
Verified
Journal Article
Closed access
PDF file
CWChris Whitton
Chris Whitton
BAB. A. Ayodele
B. A. Ayodele
PHPeta Hitchens
Peta Hitchens
EME. J. Mackie
E. J. Mackie

21 August 2015 in Journal of Orthopaedic Research
Verified
Journal Article
Open access
PDF file
MMMichiko Mirams
Michiko Mirams
BABabatunde A. Ayodele
Babatunde A. Ayodele
LTLiliana Tatarczuch
Liliana Tatarczuch
FHFrances M. Henson
Frances M. Henson
CPCharles N. Pagel
Charles N. Pagel
EMEleanor J. Mackie
Eleanor J. Mackie
During the early stages of articular osteochondrosis, cartilage is retained in subchondral bone, but the pathophysiology of this condition of growing humans and domestic animals is poorly understood. A subtractive hybridization study was undertaken to compare gene expression between the cartilage of early experimentally induced equine osteochondrosis lesions and control cartilage. Of the many putative differentially expressed genes identified, eight were confirmed by quantitative PCR analysis as differentially expressed, in addition to those already known to be associated with early lesions. Genes encoding vacuolar H+‐ATPase V0subunit d2(ATP6V0D2), cathepsin K, integrin‐binding sialoprotein, integrin αV, low density lipoprotein receptor‐related protein 4, lumican, osteopontin, and thymosin β4 (TMSB4) were expressed at higher levels in lesions than in control cartilage. These genes included 34 genes not previously identified in cartilage. Some genes identified as associated with early lesions are known chondrocyte hypertrophy‐associated genes, and in transmission electron microscopy studies normal hypertrophic chondrocytes were observed in lesions. Differential expression of ATP6V0D2 and TMSB4 in the cartilage of early naturally occurring osteochondrosis lesions was confirmed by immunohistochemistry. These results identify novel osteochondrosis‐associated genes and provide evidence that articular osteochondrosis does not necessarily result from failure of chondrocytes to undergo hypertrophy. © 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:404–411, 2016.

28 January 2020 in Equine Veterinary Journal
Verified
Journal Article
Closed access
PDF file
KLKristen A. Lloyd
Kristen A. Lloyd
BABabatunde A. Ayodele
Babatunde A. Ayodele
PHPeta Hitchens
Peta Hitchens
CBCathy Beck
Cathy Beck
EMEleanor J. Mackie
Eleanor J. Mackie
CWChris Whitton
Chris Whitton

1 December 2017 in Bone Reports
Verified
Journal Article
Open access
BABabatunde A. Ayodele
Babatunde A. Ayodele
MMMichiko Mirams
Michiko Mirams
CPCharles N. Pagel
Charles N. Pagel
EMEleanor J. Mackie
Eleanor J. Mackie
Chondrocyte hypertrophy makes important contributions to bone development and growth. We have investigated a number of novel cartilage genes identified in a recent transcriptomic study to determine whether they are differentially expressed between different zones of equine foetal growth cartilage. Twelve genes (ATP6V0D2, BAK1, DDX5, GNB1, PIP4K2A, RAP1B, RPS7, SRSF3, SUB1, TMSB4, TPI1 and WSB2) were found to be more highly expressed in the zone of hypertrophic chondrocytes than in the reserve or proliferative zones, whereas FOXA3 and SERPINA1 were expressed at lower levels in the hypertrophic zone than in the reserve zone. ATP6V0D2, which encodes vacuolar H+ ATPase (V-ATPase) V0 subunit d2 (ATP6V0D2), was selected for further study. Immunohistochemical analysis of ATP6V0D2 in growth cartilage showed stronger staining in hypertrophic than in reserve zone or proliferative chondrocytes. Expression of ATP6V0D2 mRNA and protein was up-regulated in the mouse chondrocytic ATDC5 cell line by conditions inducing expression of hypertrophy-associated genes including Col10a1 and Mmp13 (differentiation medium). In ATDC5 cells cultured in control medium, knockdown of Atp6v0d2 or inhibition of V-ATPase activity using bafilomycin A1 caused a decrease in Col2a1 expression, and in cells cultured in differentiation medium the two treatments caused a decrease in nuclear area. Inhibition of V-ATPase, but not Atp6v0d2 knockdown, prevented the upregulation of Col10a1, Mmp13 and Vegf by differentiation medium, while Atp6v0d2 knockdown, but not inhibition of V-ATPase, caused an increase in the number of ATDC5 cells cultured in differentiation medium. These observations identify ATP6V0D2 as a novel chondrocyte hypertrophy-associated gene. The results are consistent with roles for V-ATPase, both ATP6V0D2-dependent and -independent, in supporting chondrocyte differentiation and hypertrophy.

16 July 2018 in Cellular Microbiology
Verified
Journal Article
Closed access
PDF file
Nidhish FrancisNidhish Francis
Nidhish Francis
BABabatunde A. Ayodele
Babatunde A. Ayodele
NONeil O'Brien-Simpson
Neil O'Brien-Simpson
WBWalter Birchmeier
Walter Birchmeier
RPRobert N. Pike
Robert N. Pike
EMEleanor J. Mackie
Eleanor J. Mackie

31 March 2023 in Journal of Periodontal Research
Verified
Journal Article
Open access
Nidhish FrancisNidhish Francis
Nidhish Francis
RSReza Sanaei
Reza Sanaei
BABabatunde A. Ayodele
Babatunde A. Ayodele
NONeil O'Brien-Simpson
Neil O'Brien-Simpson
DFDavid P. Fairlie
David P. Fairlie
CPCharles Neil Pagel
Charles Neil Pagel
Background and Objective: Protease‐activated receptor‐2 (PAR2), a pro‐inflammatory G‐protein coupled receptor, has been associated with pathogenesis of periodontitis and the resulting bone loss caused by oral pathogens, including the keystone pathogen Porphyromonas gingivalis (P. gingivalis). We hypothesised that administration of a PAR2 antagonist, GB88, might prevent inflammation and subsequent alveolar bone resorption in a mouse model of periodontal disease.Methods: Periodontitis was induced in mice by oral inoculations with P. gingivalis for a total of eight times over 24 days. The infected mice were treated with either GB88 or vehicle for the duration of the trial. Following euthanasia on day 56, serum was collected and used for the detection of mast cell tryptase. The right maxillae were defleshed and stained with methylene blue to measure the exposed cementum in molar teeth. The left maxillae were prepared for cryosections followed by staining for tartrate‐resistant acid phosphatase to identify osteoclasts or with toluidine blue to identify mast cells. Reverse transcription quantitative PCR (RT‐qPCR) was used to quantify the expression of inflammatory cytokines in the gingival tissue. Supernatants of T‐lymphocyte cultures isolated from the regional lymph nodes were assayed using a cytometric bead array to measure the Th1/Th2/Th17 cytokine levels.Results: Measurement of the exposed cementum showed that GB88 reduced P. gingivalis‐induced alveolar bone loss by up to 69%. GB88 also prevented the increase in osteoclast numbers observed in the infected mice. Serum tryptase levels were significantly elevated in both the infected groups, and not altered by treatment. RT‐qPCR showed that GB88 prevented the upregulation of Il1b, Il6, Ifng and Cd11b. In T‐lymphocyte supernatants, only IFNγ and IL‐17A levels were increased in response to infection, but this was prevented by GB88 treatment.Conclusions: GB88 significantly reduced osteoclastic alveolar bone loss in mice infected with P. gingivalis, seemingly by preventing the upregulation of several inflammatory cytokines. PAR2 antagonism may be an effective treatment strategy for periodontal disease.